August 30, 2013
Life Sciences Intellectual Property Review
This article from LSIPR discusses a recent amici curiae submitted to a U.S. district court in support of Ambry Genetics and Gene by Gene. Finnegan partner Anthony C. Tridico, Ph.D. provided commentary on the patent infringement cases against Myriad Genetics, Inc. and the potential impact of the amici curiae submitted by industry groups, including the American Civil Liberties Union (ACLU), Association for Molecular Pathology (AMP), and the Public Patent Foundation (PUBPAT). Tridico said Ambry’s argument that Myriad’s method claims are in breach of the First Amendment is “absolutely not something you see in most cases.” He added, “At this point, the parties are only at the preliminary injunction stage. Since public interest is a factor for preliminary injunctions, [the brief] may be considered by the judge in his determination of the public interest in granting the preliminary injunction.” Tridico also noted that even in light of the amici, “It is still a patent infringement case to be decided on the merits.”
Commentary
April 11, 2024
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.